The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.

Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M.

Eur J Cancer . 2020 Jul;134:99-106. doi: 10.1016/j.ejca.2020.04.020. Epub 2020 Jun 2.

https://pubmed.ncbi.nlm.nih.gov/32502940/